KF31327
| 中文名称 | KF31327 |
|---|---|
| 中文同义词 | 西地那非杂质35;化合物 T26273;硫喹哌非 |
| 英文名称 | KF31327 |
| 英文同义词 | KF31327;3-ethyl-8-[[2-[4-(hydroxymethyl)piperidin-1-yl]phenyl]methylamino]-1H-imidazo[4,5-g]quinazoline-2-thione;Thioquinapiperifil;2H-Imidazo[4,5-g]quinazoline-2-thione, 3-ethyl-1,3-dihydro-8-[[[2-[4-(hydroxymethyl)-1-piperidinyl]phenyl]methyl]amino]-;KF-31327 free base;Thioquinapiperfil |
| CAS号 | 220060-39-9 |
| 分子式 | C24H28N6OS |
| 分子量 | 448.58 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 220060-39-9.mol |
| 结构式 |  |
KF31327 性质
|
PDE5 0.074 nM (IC 50 ) |
PDE1 380 nM (IC 50 ) |
PDE2 670 nM (IC 50 ) |
PDE3 38 nM (IC 50 ) |
PDE4 800 nM (IC 50 ) |
Thioquinapiperifil can be found in dietary supplements.
Thioquinapiperifil (KF31327 free base) (0.1-10 μM) concentration dependently inhibits platelet aggregation. In the absence of nitroglycerin, higher concentrations 1 and 10 μM of Thioquinapiperifil (KF31327 free base) are required to inhibit platelet aggregation.
Thioquinapiperifil (KF31327 free base) and shows significant increase in cyclic GMP at 10 μM. After 5 min incubation, the mean cyclic GMP levels of Thioquinapiperifil (KF31327)-treated cells is 0.95±0.17 pmol/10
8
cells.